NCT07216066View on ClinicalTrials.gov

First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

46

Participants

Timeline

Start Date

November 24, 2025

Primary Completion Date

May 28, 2029

Study Completion Date

May 28, 2029

Conditions

Parkinsons Disease

Interventions

DRUG

ALN-SNCA

Administered per the protocol

DRUG

Placebo

Administered per the protocol

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY